5 hours ago
1
Dmitry Vinogradov
- Shares of Cartesian Therapeutics (NASDAQ:RNAC) climbed ~23% on Wednesday after Wedbush initiated the Frederick, Maryland-based biotech with an Overweight recommendation and a $38 price target, citing its mRNA cell therapy platform targeted at autoimmune diseases.
- Wedbush analyst Martin Fan argued
English (US) ·